ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
05 Nov 2023 16:40

HK Connect SOUTHBOUND (To 3 Nov 23); CNOOC & China Mobile AGAIN See Outflows, SMIC & Xiaomi See Buys

HK Connect SOUTHBOUND flows saw net inflows for the 15th week in a row  with +HKD 8.5bn. H/A pairs saw Hs outperform their As by 56bp. Flows are...

Logo
494 Views
Share
05 Nov 2023 10:10

Hong Kong Connect Flows (Nov 3rd): Li Ning, SMIC, Xiaomi

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Li Ning, Semiconductor Manufacturing International, Xiaomi,...

Logo
588 Views
Share
05 Nov 2023 10:05

HK Short Interest Weekly: Yankuang Energy, CCB, Bidu, Petrochina

We analyzed the latest HK SFC report for aggregate short position as of Oct 27th and highlight short interest changes in Yankuang Energy, CCB,...

Logo
490 Views
Share
bullishWuxi Biologics
05 Nov 2023 08:25

ECM Weekly (5th Nov 2023)- Midea, WuxiXDC, Cello, Honasa, Qyuns, Ecopro, Lalatech, Mankind, TWE, VNT

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
410 Views
Share
bearishWuXi XDC Cayman
01 Nov 2023 18:21

WuXi XDC IPO: The Bear Case

The bear case rests on margins on a downward trend, large customer concentration, high related party transactions and volatile FCF generation.

Logo
479 Views
Share
x